CJC-1295 / Ipamorelin Blend
A research peptide blend combining CJC-1295 (Mod GRF 1-29), a GHRH analogue, with Ipamorelin, a selective ghrelin receptor agonist, to achieve synergistic growth hormone release through dual-pathway activation of pituitary somatotrophs.
CJC-1295 / Ipamorelin is one of the most widely studied growth hormone secretagogue blends in peptide research. By combining a growth hormone-releasing hormone (GHRH) analogue with a selective ghrelin mimetic, this blend activates two complementary signaling cascades on pituitary somatotrophs, producing amplified GH pulses that exceed the output of either peptide alone.
Overview
The CJC-1295 / Ipamorelin blend pairs two peptides that act through mechanistically independent receptors on the same target cell population -- anterior pituitary somatotrophs. CJC-1295 (Mod GRF 1-29) is a truncated and amino-acid-substituted analogue of native GHRH(1-44) with improved metabolic stability. Ipamorelin is a pentapeptide growth hormone secretagogue first characterized by Raun et al. (1998) as a highly selective GHS-R1a agonist that releases GH without significantly affecting ACTH, cortisol, prolactin, or FSH levels.
The rationale for combining these two peptides rests on decades of research demonstrating that GHRH and ghrelin-pathway agonists produce synergistic -- not merely additive -- GH release when co-administered. This synergy was first characterized systematically by Bowers et al. (1990), who demonstrated that growth hormone-releasing peptides (GHRPs) and GHRH activate distinct intracellular signaling cascades that converge to amplify GH secretion.
Mechanism of Action
The synergistic mechanism operates through convergent signaling on somatotroph cells:
GHRH Receptor Pathway (CJC-1295): CJC-1295 binds the GHRH receptor (GHRH-R), a class B G protein-coupled receptor, activating adenylyl cyclase through Gs-alpha coupling. This increases intracellular cAMP, which activates protein kinase A (PKA), ultimately promoting GH gene transcription and vesicular GH release. GHRH signaling also drives somatotroph proliferation and sets the amplitude baseline for GH pulses.
Ghrelin Receptor Pathway (Ipamorelin): Ipamorelin activates GHS-R1a, a class A GPCR that couples primarily through Gq/11-alpha. This activates phospholipase C (PLC), generating inositol trisphosphate (IP3) and diacylglycerol (DAG), which mobilize intracellular calcium stores and activate protein kinase C (PKC). The calcium surge triggers immediate exocytosis of pre-formed GH vesicles.
Synergistic Convergence: The two pathways converge at multiple points. The cAMP/PKA pathway (GHRH) enhances GH synthesis and primes vesicles for release, while the IP3/calcium pathway (ghrelin) triggers rapid exocytosis. Co-activation produces a GH pulse substantially greater than the sum of individual responses, as demonstrated by Bowers et al. (1990). Additionally, ghrelin receptor activation antagonizes somatostatin signaling at the hypothalamic level, reducing the inhibitory tone that would otherwise limit GHRH-driven GH release.
Reconstitution Calculator
CJC-1295 / Ipamorelin Blend
**CJC-1295 / Ipamorelin** is one of the most widely studied growth hormone secre
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Pulsatile GH Physiology
The blend approach is designed to recapitulate physiological GH pulsatility rather than producing sustained, tonic GH elevation. Research on the somatotroph axis indicates that pulsatile GH exposure is more effective than continuous exposure for activating hepatic GH receptors and stimulating IGF-1 production. The short half-lives of both components (CJC-1295 no DAC ~30 min, Ipamorelin ~2 hours) naturally create pulse-like GH release kinetics.
Ipamorelin Selectivity
Raun et al. (1998) characterized Ipamorelin as a highly selective growth hormone secretagogue in swine and rat models. Unlike earlier GHRPs such as GHRP-6 and GHRP-2, Ipamorelin demonstrated potent GH release without significant increases in ACTH, cortisol, or prolactin at GH-releasing doses. This selectivity profile makes it an attractive component for blend formulations where minimizing off-target hormonal effects is desirable.
Clinical GH Secretagogue Pharmacology
Teichman et al. (2006) conducted clinical studies evaluating the pharmacokinetics and pharmacodynamics of CJC-1295 in healthy human subjects. Subcutaneous administration produced dose-dependent increases in GH, IGF-1, and IGFBP-3 levels that persisted for several days when using the DAC-conjugated form. The study established the clinical viability of modified GHRH analogues as sustained GH secretagogues.
Growth Hormone Synergy
The foundational observation that GHRH and GHRPs produce synergistic GH release was established by Bowers et al. (1990), who showed that co-administration of GHRH with GH-releasing peptides in human subjects produced GH peaks far exceeding those achieved with either agent alone. This work established the principle that dual-pathway activation creates a multiplicative rather than additive effect on somatotroph output.
Safety Profile
Both components of this blend have established preclinical and clinical safety data. Ipamorelin is notable for its favorable selectivity profile, with Raun et al. (1998) demonstrating minimal impact on cortisol, ACTH, and prolactin at GH-releasing doses. CJC-1295 (no DAC) has a short half-life that limits cumulative exposure. Common observations in research settings include transient injection-site reactions, mild flushing, and transient changes in appetite. As with all GH secretagogues, potential concerns include effects on glucose metabolism and theoretical risk of promoting growth in pre-existing neoplasms.
Pharmacokinetic Profile
CJC-1295 / Ipamorelin Blend — Pharmacokinetic Curve
Subcutaneous injectionQuick Start
- Route
- Subcutaneous injection
Research Protocols
subcutaneous Injection
Subcutaneous administration produced dose-dependent increases in GH, IGF-1, and IGFBP-3 levels that persisted for several days when using the DAC-conjugated form.
Interactions
Peptide Interactions
By combining a growth hormone-releasing hormone (GHRH) analogue with a selective ghrelin mimetic, this blend activates two complementary signaling cascades on pituitary somatotrophs, producing amplified GH pulses that exceed the output of either peptide alone.
What to Expect
What to Expect
Rapid onset expected; half-life of CJC-1295 (no DAC): ~30 min; Ipamorelin: ~2 hours indicates fast-acting pharmacokinetics
The short half-lives of both components (CJC-1295 no DAC ~30 min, Ipamorelin ~2 hours) naturally create pulse-like GH release kinetics.
Due to short half-life (CJC-1295 (no DAC): ~30 min; Ipamorelin: ~2 hours), effects are expected per-dose; consistent daily administration maintains...
Regular administration schedule required; effects are dose-dependent and do not persist between doses
Quality Indicators
What to look for
- Multiple peer-reviewed studies available
Caution
- Short half-life may require frequent dosing
- Injection site reactions reported
Frequently Asked Questions
References (3)
- [1]Bowers CY et al On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone Endocrinology (1990)
- [2]Teichman SL et al Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults J Clin Endocrinol Metab (2006)
- [3]
CJC-1295 / Hexarelin Blend
A research peptide blend combining CJC-1295 (no DAC) and Hexarelin, two growth hormone secretagogues studied for their synergistic effects on GH release, cardioprotection, and metabolic regulation. Hexarelin's strong cardiac tropism complements CJC-1295's sustained GH pulsatility for combined anabolic and cardioprotective research applications.
CJC-1295 (Mod GRF 1-29)
CJC-1295 without DAC (Modified GRF 1-29) is a synthetic analog of growth hormone-releasing hormone with four amino acid substitutions that enhance metabolic stability. It promotes pulsatile GH release with a short half-life of approximately 30 minutes.